These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 9280483

  • 1. [The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV, Kucherianu VG, Kudrin VS, Zhigal'tsev IV, Nikushkin EV, Sandalov IuG, Kaplun AP, Shvets VI.
    Biull Eksp Biol Med; 1997 Feb; 123(2):150-3. PubMed ID: 9280483
    [No Abstract] [Full Text] [Related]

  • 2. [The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV, Podgornyĭ GI, Kucherianu VG, Kudrin VS, Nikushkin EV, Zhigal'tsev IV, Sandalov IuG, Kaplun AP, Shvets VI, Kryzhanovskiĭ GN.
    Biull Eksp Biol Med; 1996 Dec; 122(12):614-7. PubMed ID: 9280455
    [No Abstract] [Full Text] [Related]

  • 3. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
    Mizukawa K, Ogawa N, Sora YH.
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
    [Abstract] [Full Text] [Related]

  • 4. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG, Kryzhanovskiĭ GN, Kudrin VS, Iurasov VV, Nikushkin EV, Zhigal'tsev IV.
    Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
    [No Abstract] [Full Text] [Related]

  • 5. [The effect of liposomal form of L-Dopa on the development of parkinsonian syndrome in mice].
    Kucherianu VG, Iurasov VV, Kryzhanovskiĭ GN, Nikushkin EV, Zhigal'tsev IV, Kaplun VP, Shvets VI.
    Biull Eksp Biol Med; 1997 Jan; 123(1):29-33. PubMed ID: 9213451
    [No Abstract] [Full Text] [Related]

  • 6. Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
    Fujitake J, Kuno S, Mizuta E.
    Adv Neurol; 1990 Jan; 53():225-9. PubMed ID: 2239462
    [No Abstract] [Full Text] [Related]

  • 7. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
    Mura A, Feldon J, Mintz M.
    Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571
    [Abstract] [Full Text] [Related]

  • 8. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Aug; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 9. [The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, liposomes with L-DOPA and "empty" liposomes on the phospholipid composition of the murine liver].
    Podgornyĭ GN, Namestnikova IV, Sliusar' NN.
    Eksp Klin Farmakol; 1999 Aug; 62(1):41-4. PubMed ID: 10198765
    [Abstract] [Full Text] [Related]

  • 10. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 11. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M, Rojas P, Kravzov J, Rios C.
    Proc West Pharmacol Soc; 1993 Apr; 36():289-91. PubMed ID: 7690973
    [No Abstract] [Full Text] [Related]

  • 12. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.
    Byler SL, Boehm GW, Karp JD, Kohman RA, Tarr AJ, Schallert T, Barth TM.
    Behav Brain Res; 2009 Mar 17; 198(2):434-9. PubMed ID: 19070633
    [Abstract] [Full Text] [Related]

  • 13. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN, Thakar JH, Grimes JD.
    Adv Neurol; 1990 Mar 17; 53():219-23. PubMed ID: 2239461
    [No Abstract] [Full Text] [Related]

  • 14. [Evaluation of the capability of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pyridine derivatives to evoke parkinsonism].
    Lermontiva NN, Soliakov LS, Bachurin SO, Tkachenko SE, Serkova TP.
    Biull Eksp Biol Med; 1989 Jun 17; 107(6):699-701. PubMed ID: 2790166
    [Abstract] [Full Text] [Related]

  • 15. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
    Goshima Y, Misu Y, Arai N, Misugi K.
    Jpn J Pharmacol; 1991 Jan 17; 55(1):93-100. PubMed ID: 1645816
    [Abstract] [Full Text] [Related]

  • 16. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
    Lermontova NN, Soliakov LS, Bachurin SO, Serkova TP, Petrova LN, Dranyĭ OA, Tkachenko SE, Kalashnikov VV.
    Biull Eksp Biol Med; 1990 Oct 17; 110(10):397-9. PubMed ID: 2279092
    [Abstract] [Full Text] [Related]

  • 17. [The role of the system of reverse capture of dopamine in the development of experimental Parkinsonism under the effect of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and its pyridine analogs].
    Bachurin SO, Soliakov LS, Lermontova NN, Tkachenko SE, Kalashnikov VV, Serkova TP, Petrova LN.
    Dokl Akad Nauk SSSR; 1989 Oct 17; 307(3):740-3. PubMed ID: 2806070
    [No Abstract] [Full Text] [Related]

  • 18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct 17; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 19. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice.
    Kirchhoff J, Mørk A, Brennum LT, Sager TN.
    Neuroreport; 2009 Mar 25; 20(5):482-6. PubMed ID: 19262413
    [Abstract] [Full Text] [Related]

  • 20. Metabolism of adenosine increase in the striatum in common marmoset parkinsonism induced by MPTP.
    Nomoto M, Shimizu T, Iwata S, Kaseda S, Fukuda T.
    Adv Neurol; 1999 Mar 25; 80():125-8. PubMed ID: 10410711
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.